Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on December 1, 2015. The report addresses Item 8.01 (Other Events) regarding the status of the Company's Phase 3 AFFINITY clinical trial.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements.
Material Changes and Clinical Trial Status
- Trial Continuation: The Phase 3 AFFINITY trial is continuing based on a pre-planned interim futility analysis of the intent-to-treat population.
- Safety Review: The Data Monitoring Committee identified no new safety issues in the final safety review.
- Subpopulation Analysis: An analysis of a prospectively defined subpopulation of men with multiple poor prognostic risk factors showed that the combination of custirsen and cabazitaxel did not meet the rigorous criteria to demonstrate an improvement in overall survival. The criteria required a hypothesized hazard ratio of less than 0.69 and a one-sided p-value of less than 0.015.
- Blinding Status: Both the Data Monitoring Committee and the Company remain blinded to all analyses.
Guidance, Outlook, and Risks
Final results for the AFFINITY trial are expected in the second half of 2016, contingent upon the timing of the event-driven final analysis. The primary risk highlighted is the failure of the drug combination to meet efficacy criteria in a specific high-risk subpopulation, though the overall trial continues.
Key Facts for Investor Verification
- Verify the specific criteria and statistical thresholds used for the subpopulation analysis.
- Monitor the timeline for the event-driven final analysis expected in the second half of 2016.
- Review the full press release (Exhibit 99.1) for additional details on the interim futility analysis.
- Confirm the Company's cash runway given the lack of immediate positive clinical data in the subpopulation.